Table 2

 Baseline demographic and descriptive characteristics

CharacteristicTotal (n = 84)Placebo (n = 39)Etanercept (n = 45)
*p<0.05 versus placebo, by analysis of variance (ANOVA); **p<0.01 versus placebo, by ANOVA; †one patient in each group took more than one DMARD.
DMARD, disease modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug.
Age (years), mean (SD)43.2 (10.6)40.7 (11.4)45.3 (9.5)*
Sex (men/women), %79/2177/2380/20
Race (white/other), %94/695/593/7
Disease duration (years), mean (SD)12.5 (8.9)9.7 (8.2)15.0 (8.8)**
Concomitant use of DMARD,† No (%)32 (38)16 (41)16 (36)
    Hydroxychloroquine1 (1)1 (3)0
    Methotrexate11 (13)5 (13)6 (13)
    Sulfasalazine22 (26)11 (28)11 (24)
Concomitant use of oral NSAID, No (%)73 (87)33 (85)40 (89)
Concomitant use of corticosteroid, No (%)13 (15)6 (15)7 (16)
Mean scores on ASAS components:
    Spinal inflammation65.462.967.5
    Nocturnal and total back pain58.256.160.0
    Patient global assessment64.663.465.6
    Functional impairment58.857.260.2
Mean BASDAI scores overall59.958.661.0
BASDAI scores <40, No (%)10 (12)5 (13)4 (9)